Sector News

Medtronic Acquires Advanced Uro-Solutions

February 24, 2015
Life sciences
Medtronic plc today announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.
 
Advanced Uro-Solutions develops and manufactures the NURO(TM) percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. This therapy is 510(k) cleared by the FDA to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.  Medtronic is preparing to launch the NURO system in the U.S. within the next 12 months.
 
More than 37 million adults in the United States – one in six – suffer from OAB.1,2  By 2018, it is estimated that 546 million people worldwide will be affected by OAB.3
 
“The acquisition of Advanced Uro-Solutions expands Medtronic’s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder,” said Linnea Burman, vice president and general manager, gastro/urology therapies at Medtronic. “Medtronic continues to invest in fully-implantable bladder control and bowel control therapies, and the addition of the NURO system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation.”
 
Since 2009, Advanced Uro-Solutions has been led by two founders, Dr. Brent Laing and Dr. John Green.
 
“Studies show that roughly 80 percent of patients prescribed oral medications to treat their OAB symptoms have stopped taking them at 12 months, and Medtronic shares our commitment to advancing neuromodulation and increasing patient access to advanced solutions intended to treat their symptoms,” said Dr. John Green, former chairman and CEO of Advanced Uro-Solutions. “We are excited to take this step toward making this important therapy available to patients around the world.”
 
Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company’s Neuromodulation division includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.
 
Medtronic will include revenue from the Advanced Uro-Solutions product line as part of the Neuromodulation division within the Restorative Therapies Group segment.  The transaction is expected to meet Medtronic’s long-term financial metrics, and the annualized earnings impact of this acquisition is not expected to be material.
 
Source: Medtronic

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]